After entering patients with acute coronary syndrome, the drug can exert its effect and take effect quickly without liver metabolic activation, and can rapidly bind to P2Y12 adenosine diphosphate receptor and play the role of antiplatelet over aggregation [8]. The gene discussed is P2RY12; the disease is acute coronary syndrome.